Boothbay Fund Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Boothbay Fund Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,146	Closed	-$230K	–	2308
2021 Q3	$230K	Buy	1,146 +213	+23%	+$50.6K	0.01%	1494
2021 Q2	$239K	Buy	933 +363	+64%	+$90.6K	0.01%	1413
2021 Q1	$151K	Buy	+570	New	+$180K	0.01%	1418
2020 Q4	–	Sell	-1,262	Closed	-$308K	–	1471
2020 Q3	$308K	Buy	1,262 +855	+210%	+$266K	0.02%	798
2020 Q2	$117K	Sell	407 -6	-1%	-$1.77K	0.01%	863
2020 Q1	$84K	Buy	+413	New	+$132K	0.01%	747
2019 Q1	–	Sell	-1,529	Closed	-$466K	–	914
2018 Q4	$466K	Buy	+1,529	New	+$494K	0.07%	279
2018 Q3	–	Sell	-665	Closed	-$243K	–	975
2018 Q2	$243K	Buy	+665	New	+$237K	0.02%	552

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's EIGR Position: Q4 2021 in Review

Boothbay Fund Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 1,146 shares — an estimated $230K sold.

Boothbay Fund Management first reported a position in EIGR in Q2 2018 and held it in 8 quarters. The position peaked at $466K in Q4 2018. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

Boothbay Fund Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Boothbay Fund Management sold 1,146 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $230K.
Boothbay Fund Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2018 and held it in 8 quarters.
Boothbay Fund Management's Eiger BioPharmaceuticals, Inc. position peaked at $466K in Q4 2018.
85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.